Results 71 to 80 of about 105,814 (267)
The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications. [PDF]
Clin Transl SciABSTRACT Ecopipam is a first‐in‐class dopamine D1 receptor antagonist under investigation for the treatment of Tourette syndrome. This open‐label, fixed‐sequence, three‐cohort study evaluated whether ecopipam induces or inhibits cytochrome P450 (CYP) 1A2, CYP2B6, CYP2C19, CYP2D6, CYP3A4, organic anion‐transporting polypeptide (OATP) 1B1, and p ...
Schmith VD +4 more
europepmc +2 more sources
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial. [PDF]
, 2015 BackgroundImprovement in renal function and decreases in serum uric acid (SUA) have been reported following prolonged high-intensity statin (HMG-CoA reductase inhibitor) therapy.
Deedwania, Prakash C +4 more
core
Az atorvastatin/amlodipin fix kombináció versus az atorvastatinterápia a terápiahűség tükrében [PDF]
, 2016 Absztrakt Bevezetés: A hypertonia és a dyslipidaemia módosítható cardiovascularis kockázati tényezők. Hazánkban a hypertonia és a dyslipidaemia egyaránt népbetegségnek számítanak.
Ferenci, Tamás, Simonyi, Gábor
core +1 more source
Advanced Science, EarlyView.Cholesterol is revealed as a multitasking fuel for lung adenocarcinoma brain metastasis: it locks EGFR at the membrane to sustain AKT/NF‐κB–driven glycolysis and EMT, loosens the blood–brain barrier by promoting Claudin‐5 loss, and rewires microglia through IL‐4R lipid‐raft–JAK1/STAT6 signaling.
Ying Chen +14 more
wiley +1 more source
Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients
Chinese Medical Journal, 2015 Objective: Statins are still underused for the prevention of cardiovascular disease (CVD) in China. Hence, we conducted a systemic review on the pharmacology, clinical efficacy, and adverse events of atorvastatin, as well as on patient adherence.
Yi-Cong Ye +2 more
doaj +1 more source
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis
Arthritis &Rheumatology, Accepted Article.Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane +33 more
wiley +1 more source
Scientific Reports, 2019 Atorvastatin, a favored option for hyperlipidemia exhibits the problem of poor gastric solubility and low absolute bioavailability (12%) along with higher pre-systemic clearance (>80%).
Manu Sharma, Isha Mehta
semanticscholar +1 more source
Serum Proteomic Signatures of RA Risk and Response: Analysis of the APIPPRA Trial
Arthritis &Rheumatology, Accepted Article.Objective To identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at‐risk individuals. Methods A total of 440 serum samples from 118 APIPPRA study participants were selected from baseline to RA onset for 46 RA progressors or to study end for 72 participants who did not develop RA ...
Marianna Jasenecova +9 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
European Journal of Medical Research, 2023 Introduction Atorvastatin is regarded as the most frequently prescribed statin worldwide for dyslipidemia. However, clinical response and risk of adverse effects to statin therapy are associated with genetic variations.
Mohammed G. Maslub +3 more
doaj +1 more source